Sus Clinicals, Inc.
Company Management

Sus Clinicals, Inc.

Research Services Cincinnati, Ohio, United States 14 employees
Employees
14
Contacts
4
Emails
4
Phones
1

Sus Clinicals, Inc. Overview

Headquarters
Cincinnati, Ohio, United States
Industry
Research Services
Employees
14
Founded
2020
Funding
3.5M
Company Email
Available in AeroLeads
NAICS
Scientific Research and Development Services
Research and Development in the Physical, Engineering, and Life Sciences
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Keywords

About Sus Clinicals, Inc.

Sus Clinicals solves major problems in qualifying new cancer drugs, devices, diagnostics and therapies. Using a proprietary model of testing on genetically-modified pigs pioneered at the University of Illinois, Sus Clinicals leverages the inherent advantages of a patent-pending large animal testing methodology combined with novel clinical approaches to reduce false positives, model the interactions of multiple diseases, and accelerate progress toward human trials for the most promising therapies.

Sus Clinicals, Inc. Contact Details

People in AeroLeads
4
With contact data
4
Email contacts
4
100.0% coverage
Phone contacts
1
25.0% coverage

Sus Clinicals, Inc. Org Chart

Sample employees and titles
Name Title Contact
Jessicca R. Biotech CEO "Passionate About Transformative Research That Enables Us to Help the Patients We All Serve!"
Email
Steve Moore R&d/business Advisor, Board Member, Community Contributor
Email
Geoffrey Marshall CFO, Sus Clinicals, Inc
Email
Jeff Weedman Co-founder/executive Chair: Sus Clinicals, Inc. Ceo/founder: Weedman Ventures, Llc. Previous: Founding CEO Cintrifuse; Vice President: Procter
Email Phone

Employees by Management Level

Executive 5 profiles
VP / Head 1 profile
Director 1 profile
Senior / Lead 1 profile
Individual contributor 1 profile

Department Contact Coverage

Department Contacts Email Phone
General 3 3 2
Executive 1 1 1

Compare Similar Companies to Sus Clinicals, Inc.